Internal Medicine, Endocrinology, Diabetes, & Metabolism · Pasadena, TX
NPI
1639599632
Since 2014
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
4
Medicare group memberships
Hospitals
4
Hospital affiliations
4102 Woodlawn Ave Ste 210
Pasadena, TX, 77504
Phone (832) 240-1189
Groups this clinician bills Medicare through
Medicare paid, 2024
$314K
5,347 services
Medicare patients, 2024
464
Average age 72
Drug cost, 2024
$5.4M
5,571 prescriptions
Company payments, 2025
$7,107
From 29 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ashkan M Zand was code 99232 (hospital e&m - subsequent), 1,948 times for 240 patients. In total Ashkan M Zand billed 5,347 services in 27 codes, and Medicare paid $314K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-11-27.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 1,948 | 240 | $62.69 | $122K |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 925 | 93 | $48.30 | $45K |
| 99439 Chronic, Principal, and Transitional Care Management | Office | 877 | 92 | $37.61 | $33K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 355 | 177 | $12.69 | $4,506 |
| 99215 Office E&M - Established | Office | 270 | 126 | $137.10 | $37K |
| 99222 Hospital E&M - Initial | Facility | 251 | 212 | $104.37 | $26K |
| 99214 Office E&M - Established | Office | 224 | 115 | $97.61 | $22K |
| 99454 E&M - Miscellaneous | Office | 156 | 30 | $37.27 | $5,814 |
| 95251 Test - Miscellaneous | Office | 129 | 42 | $27.51 | $3,549 |
| 99204 Office E&M - New | Office | 37 | 37 | $131.65 | $4,871 |
| 93922 Duplex Scan - Extremity Arteries | Office | 20 | 20 | $64.97 | $1,299 |
| 99231 Hospital E&M - Subsequent | Facility | 18 | 11 | $39.72 | $715 |
| 99213 Office E&M - Established | Office | 15 | 12 | $72.39 | $1,086 |
| 99205 Office E&M - New | Office | 15 | 15 | $163.75 | $2,456 |
By year: 2022 $246K for 3,679 services; 2023 $319K for 4,839 services; 2024 $314K for 5,347 services.
Lab tests billed to Medicare, 2022
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83036 Blood Count | 15 | 12 | $9.54 | $143 |
Medicare prescription drug claims, 2024
In 2024, the drug Ashkan M Zand prescribed most often to Medicare patients was Mounjaro (Tirzepatide), with 492 prescriptions and refills. In total Ashkan M Zand wrote 5,571 Medicare prescriptions that cost $5.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Mounjaro Tirzepatide | 492 | 744 | 106 | $785K |
| Ozempic Semaglutide | 375 | 645 | 117 | $609K |
| Levothyroxine Sodium Generic | 335 | 887 | 103 | $4,442 |
| Jardiance Empagliflozin | 246 | 551 | 87 | $312K |
| Metformin Hcl Er Metformin Hcl | 244 | 683 | 82 | $3,223 |
| Glipizide Generic | 169 | 476 | 57 | $1,909 |
| Atorvastatin Calcium Generic | 154 | 410 | 59 | $1,504 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 151 | 374 | 72 | $22K |
| Tresiba Flextouch U-100 Insulin Degludec | 103 | 259 | 38 | $73K |
| Fiasp Flextouch Insulin Aspart (Niacinamide) | 97 | 208 | 37 | $78K |
| Liothyronine Sodium Generic | 89 | 215 | 30 | $2,803 |
| Pioglitazone Hcl Generic | 85 | 233 | 33 | $1,413 |
| Farxiga Dapagliflozin Propanediol | 83 | 181 | 26 | $93K |
| Glimepiride Generic | 74 | 211 | 31 | $523 |
| Tresiba Flextouch U-200 Insulin Degludec | 73 | 193 | 26 | $67K |
Brand drugs: 2,826 claims; generic drugs: 2,407 claims; opioid claims: 18.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ashkan M Zand $7,107 ($7,107 in general payments such as food, travel and fees) from 29 companies. The largest payer was Corcept Therapeutics with $3,408.
| Company | Payments | Amount |
|---|---|---|
| Corcept Therapeutics CORT | 18 | $3,408 |
| Xeris Pharmaceuticals, Inc. | 8 | $1,170 |
| Dexcom, Inc. DXCM | 20 | $842 |
| Insulet Corporation PODD | 4 | $223 |
| Recordati_rare_diseases_inc. | 4 | $201 |
| Novo Nordisk Inc NVO | 15 | $197 |
| Amgen Inc. AMGN | 12 | $186 |
| Mannkind Corporation MNKD | 6 | $140 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 4 | $94.77 |
| Ascendis Pharma Endocrinology Inc ASND | 3 | $69.24 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.